Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|13|6|413-420

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.13, Iss.6, 2013-12, pp. : 413-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery

By  

Current Drug Targets - Infectious Disorders, Vol. 3, Iss. 3, 2003-09 ,pp. : 263-271

Bentham Science Publishers

Access to resources Recommend Favorite

Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences

By  

Current Gene Therapy, Vol. 13, Iss. 6, 2013-12 ,pp. : 395-412

Bentham Science Publishers

Access to resources Recommend Favorite

Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors

By  

Current Gene Therapy, Vol. 3, Iss. 6, 2003-12 ,pp. : 567-582

Bentham Science Publishers

Access to resources Recommend Favorite

Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials

By Schork Nicholas   Topol Eric  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 2, 2010-03 ,pp. : 315-333

Taylor & Francis Ltd

Access to resources Recommend Favorite

Clinical trials involving the oncolytic virus, reovirus: ready for prime time?

By Black Allison J   Morris Don G  

Expert Review of Clinical Pharmacology, Vol. 5, Iss. 5, 2012-09 ,pp. : 517-520

Informa Healthcare

Access to resources Recommend Favorite